{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:43:17Z","timestamp":1772170997285,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2008,6,20]],"date-time":"2008-06-20T00:00:00Z","timestamp":1213920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1000095","type":"journal-article","created":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T19:38:29Z","timestamp":1213904309000},"page":"e1000095","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":80,"title":["Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia"],"prefix":"10.1371","volume":"4","author":[{"given":"Peter S.","family":"Kim","sequence":"first","affiliation":[]},{"given":"Peter P.","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Doron","family":"Levy","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2008,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"CL Sawyers","year":"2000","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00001622-200403000-00002","article-title":"Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.","volume":"16","author":"GR Angstreich","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1365-2141.2000.02216.x","article-title":"Chronic myelogenous leukaemia.","volume":"111","author":"SJ Lee","year":"2000","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.","volume":"11","author":"J Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia.","volume":"435","author":"F Michor","year":"2005","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functi onal insights and clinical implications.","volume":"12","author":"I Roeder","year":"2006","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: Principles of emergence and prevention.","volume":"102","author":"NL Komarova","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","first-page":"18326818","article-title":"Development and dynamics of robust T cell responses to CML under imatinib treatment.","volume":"PMID","author":"CI Chen","year":"2008","journal-title":"Blood [Epub ahead of print]"},{"key":"ref9","first-page":"1135","article-title":"Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.","volume":"105","author":"H Wang","year":"2005","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtbi.2005.02.015","article-title":"Post-transplantation dynamics of the immune response to chronic myelogenous leukemia.","volume":"236","author":"R DeConde","year":"2005","journal-title":"J Theor Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","article-title":"Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.","volume":"16","author":"TL Whiteside","year":"2006","journal-title":"Semin Cancer Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia.","volume":"33","author":"PD Wadhwa","year":"2006","journal-title":"Semin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/516360","article-title":"Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections.","volume":"26","author":"JM Rowe","year":"1998","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1371\/journal.pmed.0040176","article-title":"Down-regulation of the interferon signaling pathway in t lymphocytes from patients with metastatic melanoma.","volume":"4","author":"RJ Critchley-Thorne","year":"2007","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0025-5564(01)00072-4","article-title":"Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis.","volume":"173","author":"T Luzyanina","year":"2004","journal-title":"Math Biosci"},{"key":"ref16","first-page":"800","article-title":"Immunobiology: the immune system in health and disease. Garland Science Publishing. 6th edition","author":"CA Janeway","year":"2005"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1006\/jtbi.2003.3208","article-title":"Models of CD8+ responses: 1. What is the antigen-independent proliferation program.","volume":"221","author":"R Antia","year":"2003","journal-title":"J Theor Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.171.8.3928","article-title":"Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection.","volume":"171","author":"RJ De Boer","year":"2003","journal-title":"J Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1056\/NEJMp038130","article-title":"Minimal residual disease in chronic myeloid leukemia.","volume":"349","author":"B Lowenberg","year":"2003","journal-title":"N Engl J Med"},{"key":"ref20","first-page":"239","article-title":"A comparison of three methods for selecting values of input variables in the analysis of output from a computer code.","volume":"21","author":"MD McKay","year":"1979","journal-title":"Technometrics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V99.10.3861","article-title":"Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.","volume":"99","author":"E Olavarria","year":"2002","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1703222","article-title":"Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.","volume":"28","author":"B Wassmann","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2006.06.002","article-title":"The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years.","volume":"37","author":"RG Piazza","year":"2006","journal-title":"Blood Cel ls Mol Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"M Deininger","year":"2005","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.","volume":"116","author":"RT Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00262-005-0681-6","article-title":"T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.","volume":"54","author":"J Schetelig","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0268-960X(03)00007-9","article-title":"The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.","volume":"17","author":"SR Riddell","year":"2003","journal-title":"Blood Rev"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:11:44Z","timestamp":1540199504000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000095"}},"subtitle":[],"editor":[{"given":"Rob J.","family":"De Boer","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2008,6,20]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1000095","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1147258.604406","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,20]]}}}